MCID: AST005
MIFTS: 83

Asthma

Categories: Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Asthma

MalaCards integrated aliases for Asthma:

Name: Asthma 53 37 12 72 49 71 71 36 28 51 40 3 41 14 69 59 59
Chronic Obstructive Asthma 12 51 69
Bronchial Hyperreactivity 12 51 69
Asthma, Diminished Response to Antileukotriene Treatment in 53 13
Asthma, Susceptibility to 53 28
Chronic Obstructive Asthma with Acute Exacerbation 12
Chronic Obstructive Asthma with Status Asthmaticus 12
Asthma-Related Traits, Susceptibility to 53
Asthma, Nocturnal, Susceptibility to 53
Asthma, Protection Against 53
Asthma, Exercise-Induced 69
Exercise Induced Asthma 12
Exercise-Induced Asthma 12
Asthma Exercise-Induced 51
Asthma-Related Traits 53
Asthma, Bronchial 53
Asthma, Nocturnal 53
Bronchial Asthma 71

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant vs. multifactorial


Classifications:



Summaries for Asthma

MedlinePlus : 40 Asthma is a chronic disease that affects your airways. Your airways are tubes that carry air in and out of your lungs. If you have asthma, the inside walls of your airways become sore and swollen. That makes them very sensitive, and they may react strongly to things that you are allergic to or find irritating. When your airways react, they get narrower and your lungs get less air. Symptoms of asthma include Wheezing Coughing, especially early in the morning or at night Chest tightness Shortness of breath Not all people who have asthma have these symptoms. Having these symptoms doesn't always mean that you have asthma. Your doctor will diagnose asthma based on lung function tests, your medical history, and a physical exam. You may also have allergy tests. When your asthma symptoms become worse than usual, it's called an asthma attack. Severe asthma attacks may require emergency care, and they can be fatal. Asthma is treated with two kinds of medicines: quick-relief medicines to stop asthma symptoms and long-term control medicines to prevent symptoms. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Asthma, also known as chronic obstructive asthma, is related to allergic asthma and intrinsic asthma, and has symptoms including recurring periods of wheezing (a whistling sound while breathing), chest tightness and shortness of breath. An important gene associated with Asthma is IL13 (Interleukin 13), and among its related pathways/superpathways are Asthma and Cytokine Signaling in Immune system. The drugs Accolate and Advair have been mentioned in the context of this disorder. Affiliated tissues include Lung, lung and testes, and related phenotypes are immune system and respiratory system

Disease Ontology : 12 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has symptom recurring periods of wheezing (a whistling sound while breathing), has symptom chest tightness, has symptom shortness of breath, has symptom mucus production and has symptom coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.

NIH Rare Diseases : 49 Asthma is a breathing disorder that affects the airways. People with this condition experience recurrent swelling and narrowing of the airways of the lungs which is associated with wheezing, shortness of breath, chest tightness, and coughing. Most affected people have episodes of symptoms ("asthma attacks") followed by symptom-free periods; however, some may experience persistent shortness of breath in between attacks. Asthma is considered a complex or multifactorial condition that is likely due to a combination of multiple genetic, environmental, and lifestyle factors. Many people with asthma have a personal or family history of allergies, such as hay fever or eczema. Having a family member with asthma is associated with an increased risk of developing the condition. Treatment generally includes various medications, both to prevent asthma attacks and to provide quick relief during an attack. Last updated: 2/28/2016

OMIM : 53 Bronchial asthma is the most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, and dyspnea; bronchial hyperresponsiveness (BHR) as assessed by methacholine challenge test; serum IgE levels; atopy; and atopic dermatitis (Laitinen et al., 2001; Illig and Wjst, 2002; Pillai et al., 2006). See 147050 for information on the asthma-associated phenotype atopy. (600807)

CDC : 3 Asthma is a disease that affects your lungs. It causes repeated episodes of wheezing, breathlessness, chest tightness, and nighttime or early morning coughing. Asthma can be controlled by taking medicine and avoiding the triggers that can cause an attack. You must also remove the triggers in your environment that can make your asthma worse.

Novus Biologicals : 52 Asthma is a chronic lung disease that causes inflammation, thickening and narrowing of airways, as well as an overproduction of mucus. More than 300 million people worldwide suffer from asthma. Asthma symptoms include wheezing, shortness of breath, coughing and tightness of the chest. Interleukin 13 (IL-13) is the key effector cytokine in asthma. IL-13 stimulates airway fibrosis via action of matrix metalloproteinases (MMPs) on tumor transforming growth factor beta (TGN-beta), and also promotes epithelial damage, mucus production and an increased concentration of eosinophils. The inflammatory response characteristic of asthma is augmented by the production of IL-13 and other TH2 cytokines.

UniProtKB/Swiss-Prot : 71 Asthma: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.

PubMed Health : 59
About asthma: Asthma (AZ-ma) is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath, and coughing. The coughing often occurs at night or early in the morning.Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma. About 7 million of these people are children.

Wikipedia : 72 Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by... more...

Related Diseases for Asthma

Diseases related to Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 485)
# Related Disease Score Top Affiliating Genes
1 allergic asthma 35.5 CCL11 IL13 IL4R IL5 NPSR1 RNASE3
2 intrinsic asthma 34.7 IL5 RNASE3
3 cough variant asthma 34.6 IL5 RNASE3
4 ige responsiveness, atopic 34.3 ADRB2 IL13 IL4R IL5 PHF11 PLA2G7
5 status asthmaticus 34.0 ADRB2 IL5 RNASE3
6 allergic rhinitis 33.8 ALOX5 CCL11 IL13 IL4R IL5 RNASE3
7 dermatitis, atopic 33.5 CCL11 IL13 IL4R IL5 PHF11 RNASE3
8 dermatitis 33.4 CCL11 IL13 IL5 NPSR1 PHF11 RNASE3
9 allergic hypersensitivity disease 33.3 CCL11 IL13 IL4R IL5 RNASE3
10 pollen allergy 33.3 ADRB2 IL13 IL4R IL5 RNASE3
11 churg-strauss syndrome 33.1 IL5 RNASE3 TNF
12 chronic eosinophilic pneumonia 33.1 CCL11 IL5 RNASE3
13 latex allergy 33.1 IL13 IL5 RNASE3
14 rhinitis 32.7 CCL11 CYSLTR1 IL13 IL4R IL5 RNASE3
15 immune system disease 32.5 IL13 IL5 TNF
16 bronchiolitis 32.0 CCL11 IL13 IL4R IL5 RNASE3 TNF
17 bronchitis 32.0 CCL11 IL5 RNASE3 TNF
18 pulmonary disease, chronic obstructive 32.0 ADRB2 RNASE3 TNF
19 pneumonia 31.7 CCL11 IL13 IL5 TNF
20 pulmonary eosinophilia 31.7 CCL11 IL13 IL5 RNASE3
21 sinusitis 31.6 CYSLTR1 IL4R IL5 RNASE3
22 food allergy 31.6 IL13 IL5 RNASE3
23 common cold 31.5 CCL11 IL13 IL5 RNASE3
24 eosinophilic pneumonia 31.4 CCL11 IL13 IL5 RNASE3
25 conjunctivitis 31.3 CCL11 IL13 IL5 RNASE3
26 hypereosinophilic syndrome 31.2 CCL11 IL13 IL5 RNASE3
27 gastroenteritis 31.2 CCL11 IL5 RNASE3 TNF
28 esophagitis, eosinophilic, 1 31.1 CCL11 IL13 IL5 RNASE3
29 eosinophilic gastroenteritis 31.1 CCL11 IL5 RNASE3
30 esophagitis 31.1 CCL11 IL13 IL5
31 respiratory syncytial virus infectious disease 31.1 IL13 IL5
32 otitis media 31.1 CCL11 RNASE3 TNF
33 allergic conjunctivitis 31.0 CCL11 IL13 IL5 RNASE3
34 schistosomiasis 31.0 IL13 IL5 RNASE3 TNF
35 inflammatory bowel disease 31.0 ALOX5 CCL11 IL13 IL4R IL5 NPSR1
36 keratoconjunctivitis 31.0 CCL11 IL13 IL5 RNASE3 TNF
37 strongyloidiasis 31.0 CCL11 IL13 IL5
38 vernal keratoconjunctivitis 30.9 CCL11 IL13 IL5 RNASE3
39 bronchial disease 30.9 ADRB2 ALOX5 CCL11 CYSLTR1 IL13 IL5
40 chronic conjunctivitis 30.7 CCL11 IL13 IL5 RNASE3
41 paranasal sinus disease 30.6 ALOX5 IL13 IL5
42 nut allergy 29.7 IL13 IL5
43 asthma, nasal polyps, and aspirin intolerance 12.5
44 asthma-related traits 1 12.4
45 asthma-related traits 2 12.4
46 asthma-related traits 4 12.3
47 asthma-related traits 5 12.2
48 asthma-related traits 7 12.2
49 asthma-related traits 3 12.2
50 asthma-related traits 6 12.2

Comorbidity relations with Asthma via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Osteoporosis
Respiratory Failure Status Asthmaticus

Graphical network of the top 20 diseases related to Asthma:



Diseases related to Asthma

Symptoms & Phenotypes for Asthma

Symptoms via clinical synopsis from OMIM:

53
Resp:
asthma
airway hyperresponsiveness


Clinical features from OMIM:

600807

Symptoms:

12
  • recurring periods of wheezing (a whistling sound while breathing)
  • chest tightness
  • shortness of breath
  • mucus production
  • coughing

Human phenotypes related to Asthma:

31
# Description HPO Frequency HPO Source Accession
1 asthma 31 HP:0002099

UMLS symptoms related to Asthma:


labored breathing, expiratory wheeze, wheezing, spasm, snoring, sneezing, dyspnea, cyanosis, coughing

MGI Mouse Phenotypes related to Asthma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.73 NPSR1 PHF11 PLA2G7 TNF ADRB2 ALOX5
2 respiratory system MP:0005388 9.23 CCL11 CYSLTR1 IL13 IL4R IL5 NPSR1

Drugs & Therapeutics for Asthma

PubMedHealth treatment related to Asthma: 59

Asthma is a long-term disease that has no cure. The goal of asthma treatment is to control the disease. Good asthma control will:Prevent chronic and troublesome symptoms, such as coughing and shortness of breathReduce your need for quick-relief medicines (see below)Help you maintain good lung functionLet you maintain your normal activity level and sleep through the nightPrevent asthma attacks that could result in an emergency room visit or hospital stayTo control asthma, partner with your doctor to manage your asthma or your child's asthma. Children aged 10 or older—and younger children who are able—should take an active role in their asthma care.Taking an active role to control your asthma involves:Working with your doctor to treat other conditions that can interfere with asthma management.Avoiding things that worsen your asthma (asthma triggers). However, one trigger you should not avoid is physical activity. Physical activity is an important part of a healthy lifestyle. Talk with your doctor about medicines that can help you stay active.Working with your doctor and other health care providers to create and follow an asthma action plan.An asthma action plan gives guidance on taking your medicines properly, avoiding asthma triggers (except physical activity), tracking your level of asthma control, responding to worsening symptoms, and seeking emergency care when needed.Asthma is treated with two types of medicines: long-term control and quick-relief medicines. Long-term control medicines help reduce airway inflammation and prevent asthma symptoms. Quick-relief, or "rescue," medicines relieve asthma symptoms that may flare up.Your initial treatment will depend on the severity of your asthma. Followup asthma treatment will depend on how well your asthma action plan is controlling your symptoms and preventing asthma attacks.Your level of asthma control can vary over time and with changes in your home, school, or work environments. These changes can alter how often you're exposed to the factors that can worsen your asthma.Your doctor may need to increase your medicine if your asthma doesn't stay under control. On the other hand, if your asthma is well controlled for several months, your doctor may decrease your medicine. These adjustments to your medicine will help you maintain the best control possible with the least amount of medicine necessary.Asthma treatment for certain groups of people—such as children, pregnant women, or those for whom exercise brings on asthma symptoms—will be adjusted to meet their special needs.

FDA approved drugs:

(show all 16)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Accolate 17 ZAFIRLUKAST AstraZeneca September 1999|October 1996
2
Advair 17 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
3
Alvesco 17 CICLESONIDE Nycomed January 2008
4
Arnuity Ellipta 17 FLUTICASONE FUROATE GlaxoSmithKline August 2014
5
Azmacort 17 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
6
Dulera 17 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
7
Flovent Rotadisk 17 FLUTICASONE PROPIONATE GlaxoSmithKline November 1997
8
Foradil Aerolizer 17 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Metaprotereol Sulfate 17 METAPROTERENOL SULFATE Morton Grove Pharmaceuticals March 1997
10
Nucala 17 MEPOLIZUMAB GlaxoSmithKline November 2015
11
Qvar 17 BECLOMETHASONE DIPROPIONATE Ivax May 2002
12
Rayos 17 PREDNISONE Horizon Pharma July of 2012
13
Serevent 17 SALMETEROL XINAFOATE GlaxoSmithKline September 1997
14
Singulair 17 MONTELUKAST SODIUM Merck February 1998
15
Xolair 17 OMALIZUMAB Genentech June 2003
16
Zyflo 17 ZILEUTON Abbott Laboratories January 1997

Drugs for Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51333-22-3 5281004 63006
2
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53-03-2 5865
3
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
4
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 299-42-3 9294
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90-82-4 7028
7
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1 22254-24-6, 60205-81-4 43232
8
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 7487-88-9 24083
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83-43-2 6741
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-24-8 5755
11
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 158966-92-8 5281040
12
Procaterol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 72332-33-3 688561
13
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
14 Cisatracurium Approved, Experimental Phase 4 96946-41-7
15
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 5311068 56032 68602
16
Etomidate Approved Phase 4,Phase 2,Phase 3 33125-97-2 667484 36339
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 437-38-7 3345
18
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
19
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 2078-54-8 4943
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 138530-94-6, 103577-45-3 9578005
22
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2 103577-45-3 3883
23
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 242138-07-4
24
Terbutaline Approved Phase 4,Phase 3,Phase 2,Phase 1 23031-25-6 5403
25
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
26
Bambuterol Approved, Investigational Phase 4,Phase 1 81732-65-2, 81732-46-9 54766
27
Azelastine Approved Phase 4,Phase 3,Phase 2,Phase 1 58581-89-8 2267
28
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-45-6, 75614-87-8 774
29
Xylometazoline Approved, Investigational Phase 4,Phase 3 526-36-3 5709
30
Capsaicin Approved Phase 4,Phase 2,Early Phase 1 404-86-4 1548943
31
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
32 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 329-65-7
33 Fondaparinux Approved, Investigational Phase 4 104993-28-4
34
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 26787-78-0 33613 2171
35
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 69-65-8 6251 453
36
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83881-51-0 2678
37
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 73963-72-1 2754
38
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 378-44-9 9782
39
Atropine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 5908-99-6, 51-55-8 174174
40
Neostigmine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 59-99-4 4456
41
Rocuronium Approved Phase 4,Phase 3,Early Phase 1 119302-91-9, 143558-00-3 441290
42
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
43
Prilocaine Approved Phase 4 721-50-6 4906
44
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
45
Probucol Approved, Investigational Phase 4,Phase 2 23288-49-5 4912
46
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 38396-39-3, 2180-92-9 2474
47
Ketorolac Approved Phase 4,Phase 3,Phase 2,Phase 1 74103-06-3, 66635-83-4 3826
48
Desflurane Approved Phase 4 57041-67-5 42113
49
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 439-14-5 3016
50
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 6740-88-1 3821

Interventional clinical trials:

(show top 50) (show all 6516)

# Name Status NCT ID Phase Drugs
1 Assessing Decision Maker Tools for Asthma: the Asthma APGAR Unknown status NCT01446315 Phase 4
2 Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home Unknown status NCT01783132 Phase 4
3 Vitamin D for the Treatment of Severe Asthma Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
4 Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma. Unknown status NCT01939951 Phase 4
5 Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Unknown status NCT02053402 Phase 4 Vitamin D
6 A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children Unknown status NCT00624429 Phase 4 Budesonide respules
7 Inflammatory, Functional and Image Composite Measure to Define Asthma Control Unknown status NCT00597064 Phase 4 prednisone
8 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
9 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4 fluticasone/ salmeterol;fluticasone
10 Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
11 Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma Unknown status NCT01584804 Phase 4 Su-Huang antitussive capsule;Sugar pill
12 Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation Unknown status NCT02584738 Phase 4 Nebulized Magnesium Sulfate;Nebulized isotonic saline;Nebulized Salbutamol;Ipratropium bromide;Methylprednisolone or Prednisolone
13 Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma Unknown status NCT01404013 Phase 4 ICS/LABA;Montelukast;ICS/LABA and Montelukast
14 Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA) Unknown status NCT01170429 Phase 4 Procaterol hydrochloride;Meptin placebo
15 Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia Unknown status NCT02289391 Phase 4 Anesthesia induction;Anesthesia maintenance;Assisted anesthesia
16 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
17 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
18 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
19 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
20 Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis Unknown status NCT02345993 Phase 4 Extra fine Formoterol/Beclomethasone
21 Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery Unknown status NCT02110654 Phase 4 Montelukast;mometasone furoate nasal spray
22 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
23 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
24 Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children Unknown status NCT00172341 Phase 4 Staloral TM
25 Concentrations of Salmeterol in Blood and Urine Unknown status NCT00914901 Phase 4 inhaled salmeterol
26 Terbutaline Concentrations in Blood and Urine Unknown status NCT00914797 Phase 4 inhaled and oral terbutaline
27 Concentrations of Formoterol in Blood and Urine Unknown status NCT00914654 Phase 4 inhaled formoterol
28 Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics Unknown status NCT02574975 Phase 4 methacholine;adenosine monophosphate;leukotriene D4;budesonide /formoterol
29 Rapid Onset Action of Salbutamol Versus Formoterol Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
30 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
31 The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma Unknown status NCT02002754 Phase 4 Bambuterol Hydrochloride tablets
32 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control Unknown status NCT00385359 Phase 4 Albuterol
33 Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids Unknown status NCT00397267 Phase 4 inhalation of corticosteroids
34 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
35 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
36 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
37 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
38 POLlinosis and Exhaled Breath Temperature Unknown status NCT01785394 Phase 4 5 grass allergen extract
39 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
40 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
41 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
42 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4 Montelukast;Placebo
43 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
44 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
45 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
46 Airway Clearance for Prevention of COPD Exacerbation Unknown status NCT00181207 Phase 4
47 Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication Unknown status NCT00424281 Phase 4 Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
48 Middle Meatal Bacteriology During Acute Respiratory Infection in Children Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid
49 Mast Cells in Acid-induced Intestinal Permeability Unknown status NCT02664051 Phase 4 Nalcrom;placebo
50 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Unknown status NCT02371941 Phase 4 oral cromolyn sodium;Placebo

Search NIH Clinical Center for Asthma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Asthma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Asthma:
Bone marrow-derived mesenchymal stem cells for severe refractory asthma
Embryonic/Adult Cultured Cells Related to Asthma:
Mouse bone marrow-derived mesenchymal stem cells (family) PMIDs: 21653527 20801416

Cochrane evidence based reviews: asthma

Genetic Tests for Asthma

Genetic tests related to Asthma:

# Genetic test Affiliating Genes
1 Asthma, Susceptibility to 28 ADRB2 ALOX5 CCL11 HLA-G HNMT IL13 MUC7 PHF11 PLA2G7 SCGB3A2 TNF
2 Asthma 28

Anatomical Context for Asthma

MalaCards organs/tissues related to Asthma:

38
Lung, Testes, Heart, T Cells, Endothelial, Neutrophil, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Asthma:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Trachea Airway Smooth Muscle Cells Potential therapeutic candidate, affected by disease

Publications for Asthma

Articles related to Asthma:

(show top 50) (show all 6742)
# Title Authors Year
1
A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder. ( 29409976 )
2018
2
A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. ( 29331473 )
2018
3
Dexamethasone alleviates allergic asthma immature rat through Toll like receptor 4. ( 29364486 )
2018
4
Is eosinophilic esophagitis an equivalent of pollen allergic asthma? Analysis of biopsies and therapy guided by component resolved diagnosis. ( 29338961 )
2018
5
Expansion of a CD26<sup>low</sup>effector TH subset and reduction of circulating levels of sCD26 in stable allergic asthma in adults. ( 29297467 )
2018
6
Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. ( 29318574 )
2018
7
Chronic strongyloidiasis with recurrent asthma exacerbations and steroid-associated 'hives'. ( 29348277 )
2018
8
Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma. ( 29131874 )
2018
9
IgE-expressing memory B cells and plasmablasts are increased in blood of children with asthma, food allergy and atopic dermatitis. ( 29380876 )
2018
10
Airway Autoimmune Inflammatory Response (AAIR) Syndrome: An Asthma-Autoimmune Overlap Disorder? ( 29449341 )
2018
11
Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab. ( 29300536 )
2018
12
Achalasia with massive oesophageal dilation causing tracheomalacia and asthma symptoms. ( 29321968 )
2018
13
Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. ( 29446377 )
2018
14
Modeling Unobserved Heterogeneity in Susceptibility to Ambient Benzo[a]pyrene Concentration among Children with Allergic Asthma Using an Unsupervised Learning Algorithm. ( 29320438 )
2018
15
Effectiveness of Indoor Allergen Reduction in the Management of Asthma: A Systematic Review. ( 29452202 )
2018
16
Advances and Evolving Concepts in Allergic Asthma. ( 29427987 )
2018
17
An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. ( 29436901 )
2018
18
Canadian genome-wide association study and meta-analysis confirm HLA as a risk factor for peanut allergy independent of asthma. ( 29325868 )
2018
19
Activated Leukocyte Cell Adhesion Molecule Stimulates the T Cell Response in Allergic Asthma. ( 29394080 )
2018
20
Association of rhinovirus species with common cold and asthma symptoms and bacterial pathogens. ( 29111214 )
2018
21
Real world evaluation of a mobile health application in children with asthma. ( 29452259 )
2018
22
Correlation between upper and lower airway inflammations in patients with combined allergic rhinitis and asthma syndrome: A comparison of patients initially presenting with allergic rhinitis and those initially presenting with asthma. ( 29434763 )
2018
23
Does adiposity mediate the relationship between socioeconomic position and non-allergic asthma in childhood? ( 29367283 )
2018
24
Everyone with asthma should have a metered dose inhaler and a spacer. ( 29449208 )
2018
25
Biased Generation and In Situ Activation of Lung Tissue-Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma. ( 29343554 )
2018
26
Asthma mobile applications: are they ready for prime time? ( 29448115 )
2018
27
Optimal control of asthma improved eosinophilic otitis media. ( 29423372 )
2018
28
Baker's Asthma: Is the Ratio of Rye Flour-Specific IgE to Total IgE More Suitable to Predict the Outcome of Challenge Test Than Specific IgE Alone. ( 29445996 )
2018
29
Allergic asthma is associated with increased risk of infections requiring antibiotics. ( 29413341 )
2018
30
Modeling asthma: Pitfalls, promises, and the road ahead. ( 29451705 )
2018
31
Bladder pain syndrome/interstitial cystitis is associated with asthma: A case-control study. ( 29441652 )
2018
32
PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma. ( 29450204 )
2018
33
DNA methylation modules in airway smooth muscle are associated with asthma severity. ( 29449426 )
2018
34
Thunderstorm asthma: controlling (deadly) grass pollen allergy. ( 29437642 )
2018
35
Association Between Obesity and Acute Severity Among Patients Hospitalized for Asthma Exacerbation. ( 29452277 )
2018
36
Late-onset asthma: current perspectives. ( 29445292 )
2018
37
Economic Burden of Pediatric Asthma: Annual Cost of Disease in Iran. ( 29445636 )
2018
38
Exposure to diisodecyl phthalate exacerbated Th2 and Th17-mediated asthma through aggravating oxidative stress and the activation of p38 MAPK. ( 29448086 )
2018
39
Developmental endothelial locus-1 (Del-1) antagonizes Interleukin-17-mediated allergic asthma. ( 29437247 )
2018
40
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. ( 29422778 )
2018
41
Interventions to enhance the adoption of asthma self-management behaviour in the South Asian and African American population: a systematic review. ( 29449558 )
2018
42
Virome and bacteriome characterization of children with pneumonia and asthma in Mexico City during winter seasons 2014 and 2015. ( 29447223 )
2018
43
Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. ( 29302700 )
2018
44
Associations of TAP1 genetic polymorphisms with atopic diseases: asthma, rhinitis and dermatitis. ( 29416713 )
2018
45
Eosinophil-derived exosomes contribute to asthma remodelling by activating structural lung cells. ( 29451337 )
2018
46
Accuracy of serum-specific IgE test with microfluidic array enzyme-linked immunosorbent assay for diagnosing inhalant allergen sensitization in asthma and/or rhinitis allergy patients in Jakarta, Indonesia. ( 29423377 )
2018
47
IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma. ( 29319845 )
2018
48
Variability in asthma quality and costs in children with different Medicaid insurance plans in Maricopa County. ( 29451814 )
2018
49
The significance of the levels of IL-4, IL-31 and TLSP in patients with asthma and/or rhinitis. ( 28303765 )
2017
50
Effect of polymorphisms on TGFB1 on allergic asthma and helminth infection in an African admixed population. ( 28284979 )
2017